Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News CorMedix Inc CRMD

Healthcare Biotechnology
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRMD)

CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

GlobeNewswire 2 days ago

CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026

GlobeNewswire 5 days ago

CorMedix to Participate in Upcoming Investor Conferences

GlobeNewswire February 12, 2026

CorMedix Therapeutics Announces Share Repurchase Program

GlobeNewswire February 2, 2026

CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026

GlobeNewswire January 29, 2026

Lost Money on CorMedix Inc. (CRMD)? Contact Levi & Korsinsky About Fraud Investigation

Newsfile January 14, 2026

CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 9, 2026

CorMedix Therapeutics Announces Leadership and Board Updates

GlobeNewswire January 8, 2026

CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates

GlobeNewswire January 8, 2026
View More News ››

Opinion & Analysis (NDAQ:CRMD)

Interim Readout for Pharma Trial 'Delivers Home Run'

Streetwise Reports August 2, 2018

Seven biotech names on the upswing: 2016 small-cap biotech watchlist update

The Life Sciences Report March 11, 2016

CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby

The Life Sciences Report February 11, 2016
View More Opinion ››

Bullboard Posts (NDAQ:CRMD)

Sell buddy sell.

Otherwise you guys out there will be losing your shorts with this one
coolfooldumbguy - June 27, 2025

This stock is still cheap.

So that it is time to be buying this one this morning.
coolfooldumbguy - January 7, 2025

Fda approuved

Ggghjhdsfyjjfv
Nibinator - November 15, 2023

FDA news

Doesn't seem to be anyone here anymore. I thought that was pretty favourable FDA news this morning yet after an intial surge here...
Pandora - July 9, 2019

RE:1-5 reverse split

Well the one for five has happened this morning and as per normal the first direction is down. There is so much more room in that...
Pandora - March 26, 2019

RE:1-5 reverse split

That is correct -- one new share for every five shares you currently own. If one existing share is $1.80 a new share will be $1.80 x 5...
Pandora - March 15, 2019
View more Bullboard ››

Birchtech Corp.

Birchtech Corp.

Birchtech Corp., an environmental services and technology company, engages in developing and delivering solutions to the ...
View More »

Podcasts